Security
Dermata Therapeutics, Inc. Common Stock · DRMA
DRMANASDAQCommon stockCurrentCIK 1853816Updated Oct 30, 2026
Name history
Dermata Therapeutics, Inc. · through Oct 29, 2026
DRMA price & chart
Loading TradingView…
NASDAQ:DRMA on TradingView ↗About the company
Dermata Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing a first-of-its-kind skin renewal treatment which incorporates Dermata’s Bioneedle™. The Company expects to launch its first product on August 25, 2026, with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more information, or to join our mailing list, please visit http://www.dermatarx.com/.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 5,071,410Source | 6,687,344Source | 5,320,799Source | 6,640,516Source | 5,236,552Source | 7,465,652Source | 10,005,007Source | 5,179,756Source | 7,863,826Source | 3,533,888Source | 7,978,634Source | 6,944,488Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,664,127Source | — | 4,412,764Source | 6,480,930Source | — | 6,945,282Source | 9,719,268Source | — | 7,521,978Source | — | — | 6,241,294Source |
| Prepaid Expense and Other Assets, CurrentUSD | 407,283Source | 543,592Source | 593,604Source | 159,586Source | 289,452Source | 427,279Source | 285,739Source | 446,075Source | 341,848Source | 372,318Source | 540,499Source | 703,194Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,111,308Source | 1,946,116Source | 1,833,079Source | 1,026,265Source | 1,918,425Source | 1,052,649Source | 2,703,785Source | 1,371,766Source | 1,640,446Source | 1,972,794Source | 1,623,616Source | 922,634Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 84Source | 168Source | 402Source | 64Source | 69Source | 402Source | 603Source | 666Source | 266Source | 252Source | 393Source | 1,232Source |
| Additional Paid in CapitalUSD | 75,332,026Source | 67,265,462Source | 81,535,983Source | 75,294,206Source | 62,669,304Source | 81,494,203Source | 75,279,545Source | 60,329,464Source | 79,457,010Source | 67,236,181Source | 59,742,503Source | 51,613,810Source |
| Retained Earnings (Accumulated Deficit)USD | -71,372,008Source | -62,524,402Source | -78,048,665Source | -69,680,019Source | -59,351,246Source | -75,081,602Source | -67,978,926Source | -56,522,140Source | -73,233,896Source | -65,675,339Source | -53,387,878Source | -45,593,188Source |
| Stockholders' Equity Attributable to ParentUSD | 3,960,102Source | 4,741,228Source | 3,487,720Source | 5,614,251Source | 3,318,127Source | 6,413,003Source | 7,301,222Source | 3,807,990Source | 6,223,380Source | 1,561,094Source | 6,355,018Source | 6,021,854Source |
| Liabilities and EquityUSD | 5,071,410Source | 6,687,344Source | 5,320,799Source | 6,640,516Source | 5,236,552Source | 7,465,652Source | 10,005,007Source | 5,179,756Source | 7,863,826Source | 3,533,888Source | 7,978,634Source | 6,944,488Source |
| Current liabilities: | ||||||||||||
| Accounts Payable, CurrentUSD | 453,427Source | 863,595Source | 1,119,718Source | 413,687Source | 1,327,179Source | 318,331Source | 1,395,313Source | 822,546Source | 460,811Source | 808,011Source | 866,028Source | 496,702Source |
| Property, Plant and Equipment, Net | — | — | —Source | — | — | — | — | — | — | — | — | — |
| Inventory, Net | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Assets, Current | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | -12,287,461Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 37,840Source | 20,992Source | 41,780Source | 39,234Source | 43,278Source | 37,189Source | 143,732Source | 657,649Source | 522,082Source | 930,325Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -51,128Source | 102,064Source | -388,056Source | -108,512Source | 369,326Source | -18,543Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,479,718Source | -1,934,066Source | -7,757,559Source | -11,162,948Source | -6,408,931Source | -8,834,164Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,903,022Source | 8,491,764Source | 12,117,967Source | 6,886,383Source | 7,605,772Source | 4,276,652Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -576,696Source | 6,557,698Source | 4,360,408Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 4,664,127Source | 6,143,752Source | 4,412,764Source | 6,480,930Source | 6,945,282Source | 9,719,268Source | 7,521,978Source | 3,161,570Source | 7,438,135Source | 6,241,294Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | — | 824,294Source | — | 1,154,896Source | — | 1,058,662Source | — | 4,309,551Source | 3,972,140Source | 4,023,445Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 68,682Source | 52,497Source | 46,504Source | 71,638Source | 78,676Source | 36,216Source | 215,041Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,691,989Source | -3,173,156Source | -2,967,063Source | -1,701,093Source | -1,847,706Source | -2,303,587Source | -7,558,557Source | -12,287,461Source | -7,794,690Source | -9,610,913Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -9,610,913Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 9,674,486Source |
| Operating ExpensesUSD | — | — | 1,760,671Source | 3,225,653Source | 3,013,567Source | 1,772,731Source | 1,926,382Source | 2,339,803Source | 7,773,598Source | 12,513,242Source | 8,041,906Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 8,541,282Source | 12,167,852Source | 6,886,102Source | 7,605,625Source | 4,276,365Source |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | 1,256,284Source | 824,294Source | 2,801,004Source | 1,154,896Source | 1,542,658Source | 1,058,662Source | 4,843,615Source | — | — | — |
| Operating Income (Loss)USD | — | — | -1,760,671Source | -3,225,653Source | -3,013,567Source | -1,772,731Source | -1,926,382Source | -2,339,803Source | -7,773,598Source | -12,513,242Source | -8,041,906Source | -9,674,486Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,691,989Source | -3,173,156Source | -2,967,063Source | -1,701,093Source | -1,847,706Source | -2,303,587Source | -7,558,557Source | -12,287,461Source | -7,794,690Source | -9,610,913Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.65Source | -20.41Source | -0.74Source | -1.22Source | -0.48Source | -4.47Source | -8.16Source | -8.03Source | -2.67Source | -0.87Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.65Source | -20.41Source | -0.74Source | -1.66Source | -0.48Source | -4.47Source | -8.16Source | -8.03Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,026,457Source | 155,465Source | 4,022,143Source | 1,026,506Source | 3,858,921Source | 515,465Source | 926,192Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,026,457Source | 155,465Source | 4,022,143Source | 1,026,506Source | 3,858,921Source | 515,465Source | 926,192Source | 1,529,772Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | — | 824,294Source | — | 1,154,896Source | — | 1,058,662Source | — | 4,309,551Source | 3,972,140Source | 4,023,445Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 63,573Source |
| Interest Income, OtherUSD | — | — | — | 52,497Source | — | — | — | 36,216Source | — | 225,781Source | 247,216Source | — |
| Investment Income, InterestUSD | — | — | 68,682Source | 52,497Source | 46,504Source | 71,638Source | 78,676Source | 36,216Source | 215,041Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -9,610,913Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 9,674,486Source |
| Operating ExpensesUSD | — | — | 1,760,671Source | 3,225,653Source | 3,013,567Source | 1,772,731Source | 1,926,382Source | 2,339,803Source | 7,773,598Source | 12,513,242Source | 8,041,906Source | — |
| Other ExpensesUSD | — | — | — | 1,800,000Source | — | — | — | 700,000Source | 700,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 504,387Source | 2,401,359Source | 212,563Source | 617,835Source | 383,724Source | 1,281,141Source | 2,929,983Source | 8,203,691Source | 4,069,766Source | 5,651,041Source |
Offerings
Registration 333-299391
Registration 333-291740
Registration 333-292885
Filing attachments
ex107.htm · S-3 · 2026-10-09
Calculation of Filing Fee Tables S-3 Dermata Therapeutics, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Of…
Read attachment ↗ex4-1.htm · 8-K · 2026-08-17
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURIT…
Read attachment ↗ex4-2.htm · 8-K · 2026-08-17
EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURIT…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-17
EX-99.1 6 ex99-1.htm EX-99.1 Exhibit 99.1 Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules $3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESSWIRE / August 17, 2026 / Dermata Therapeutics, Inc. (Nasdaq: DRMA) (“Dermata,” or the “Company”), a science-driven leader in dermatologic solutions, today announced that it has entered into …
Read attachment ↗ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026 - Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 - - Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand - SAN DIEGO, CA, August 11, 2026 - Dermata Therapeutics, Inc. (Nasdaq: DRMA ) (“Dermata,” or the “Company”), a …
Read attachment ↗ex107.htm · S-8 · 2026-06-04
Calculation of Filing Fee Tables S-8 Dermata Therapeutics, Inc. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ──────────────────────────────────────…
Read attachment ↗